GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hunan Jingfeng Pharmaceutical Co 000908.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

5.23

-2.61%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥378.1m

FY2016FY2025

Net income

−CN¥80.9m

FY2016FY2025

Free cash flow

CN¥54.8m

FY2016FY2025

Shareholders' equity

CN¥23.1m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥378.1mCN¥416.0mCN¥656.9mCN¥840.7mCN¥811.2mCN¥877.9mCN¥1.34bnCN¥2.59bnCN¥2.58bnCN¥2.64bn
Gross profitCN¥237.8mCN¥261.0mCN¥459.0mCN¥634.8mCN¥487.5mCN¥547.4mCN¥805.6mCN¥1.95bnCN¥2.03bnCN¥2.08bn
Research and developmentCN¥11.0mCN¥19.0mCN¥52.5mCN¥35.6mCN¥38.6mCN¥252.9mCN¥191.3mCN¥156.4mCN¥93.2mCN¥113.5m
Operating income−CN¥27.9mCN¥203.9m−CN¥172.9m−CN¥68.3m−CN¥135.9m−CN¥1.12bn−CN¥908.4mCN¥254.9mCN¥258.1mCN¥440.7m
Net income−CN¥80.9mCN¥152.3m−CN¥236.1m−CN¥122.6m−CN¥163.7m−CN¥1.07bn−CN¥882.8mCN¥186.8mCN¥162.1mCN¥340.0m
Diluted earnings per share-0.090.17-0.27-0.14-0.18-1.20-0.990.210.180.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥820.0mCN¥940.0mCN¥1.06bnCN¥1.47bnCN¥1.79bnCN¥2.69bnCN¥4.35bnCN¥5.23bnCN¥4.87bnCN¥5.13bn
Cash and short-term investments—CN¥85.5mCN¥13.2mCN¥181.4mCN¥172.2mCN¥164.2mCN¥405.5mCN¥512.1mCN¥472.1mCN¥1.20bn
Total liabilitiesCN¥848.2mCN¥955.1mCN¥1.21bnCN¥1.25bnCN¥1.46bnCN¥2.05bnCN¥2.41bnCN¥2.37bnCN¥2.27bnCN¥2.52bn
Debt—CN¥198.4mCN¥593.9mCN¥598.8mCN¥873.5mCN¥1.42bnCN¥1.70bnCN¥1.77bnCN¥1.80bnCN¥1.98bn
Shareholders' equityCN¥23.1mCN¥81.8m−CN¥49.5mCN¥177.9mCN¥306.4mCN¥520.0mCN¥1.59bnCN¥2.48bnCN¥2.38bnCN¥2.39bn
Shares outstanding877m881m878m882m886m894m892m881m880m879m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥59.3m−CN¥5.6mCN¥35.1mCN¥123.3mCN¥123.8m−CN¥271.7mCN¥36.2mCN¥350.9mCN¥151.7mCN¥12.3m
Capital spending−CN¥4.6m−CN¥1.4m−CN¥10.4m−CN¥13.5m−CN¥38.1m−CN¥96.0m−CN¥113.6m−CN¥171.1m−CN¥303.2m−CN¥252.8m
Free cash flowCN¥54.8m−CN¥6.9mCN¥24.6mCN¥109.8mCN¥85.7m−CN¥367.7m−CN¥77.5mCN¥179.8m−CN¥151.6m−CN¥240.5m
Dividends paid−CN¥10.5m−CN¥13.4m−CN¥23.6m−CN¥39.6m−CN¥91.5m−CN¥89.2m−CN¥86.6m−CN¥102.1m−CN¥91.4m−CN¥132.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥94.9mCN¥107.5mCN¥106.3mCN¥88.5mCN¥83.3mCN¥100.1mCN¥121.3mCN¥92.1m
Gross profitCN¥57.4mCN¥74.5mCN¥62.1mCN¥55.7mCN¥53.3mCN¥66.7mCN¥84.3mCN¥53.1m
Operating income−CN¥460,956CN¥7.3m−CN¥19.9mCN¥614,213−CN¥17.6m−CN¥7.6mCN¥232.9m−CN¥9.4m
Net incomeCN¥2.2mCN¥3.7m−CN¥36.3m−CN¥12.0m−CN¥20.7m−CN¥11.9mCN¥258.6m−CN¥15.8m
Diluted earnings per share0.000.00-0.04-0.01-0.02-0.010.29-0.02
Cash from operations———CN¥125.0m−CN¥13.0mCN¥11.0m—CN¥6.0m
Capital spending−CN¥49.0m−CN¥3.0m−CN¥3.0m—————
Total assetsCN¥2.44bnCN¥2.51bnCN¥820.0mCN¥878.0mCN¥904.1mCN¥923.3mCN¥940.0mCN¥1.02bn
Cash and short-term investments———CN¥26.1mCN¥25.6mCN¥56.0mCN¥85.5mCN¥21.6m
Debt———CN¥271.7mCN¥166.0mCN¥178.3mCN¥191.7mCN¥266.8m
Shareholders' equityCN¥2.09bnCN¥2.09bnCN¥23.1mCN¥37.3mCN¥49.3mCN¥69.9mCN¥81.8m−CN¥155.7m

Financial ratios

Data as of 13 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin62.9%62.7%69.9%75.5%60.1%62.3%—
Operating margin-12.5%49.2%-23.5%-4.0%-8.5%-118.9%—
Net margin-21.4%36.6%-35.9%-14.6%-20.2%-121.7%—
Return on equity-349.5%186.2%477.0%-68.9%-53.4%-205.5%—
Return on assets-9.9%16.2%-22.3%-8.3%-9.1%-39.7%—
Free cash flow yield1.3%-0.1%0.9%2.7%3.1%-3.4%—
Revenue growth-9.1%-36.7%-21.9%3.6%-7.6%-34.7%—
Earnings growth-153.1%-164.5%92.6%-25.1%-84.7%21.0%—
Current ratio0.34x0.25x0.21x0.53x0.50x0.55x—
Debt to equity—2.34x-5.42x1.60x1.56x2.74x1.16x
Equity ratio2.8%8.7%-4.7%12.1%17.1%19.3%—
Interest coverage-1.56x5.08x-3.87x-0.63x-0.81x-9.65x—
R&D as a share of sales2.9%4.6%8.0%4.2%4.8%28.8%—
Buybacks as a share of market value0.5%-0.3%0.3%0.5%0.8%-0.2%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-23.4%-15.5%-17.1%
Operating income-25.8%-52.3%—
Net income-12.9%-40.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin62.8%69.5%66.0%73.7%
Operating margin22.2%-2.8%-33.3%-5.5%
Net margin9.0%-12.5%-38.2%-8.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-77.928.3-12.1-22.9-23.6-3.8-3.820.932.927.0
Price to sales16.710.44.33.34.84.62.51.52.13.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 23 Aug 2018.

FY2018FY2016FY2004FY2001
Paid in the year0.010.0910.0360.032
  • 11-for-10 split · 23 Jun 2016
  • 1-to-1 reverse split · 10 Jun 2008

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.